Form 4 for PLX Protalix BioTherapeutics, Inc.
Accepted 2025-09-04 00:00:00 ET · period of report 2025-09-03 · accession 0001415889-25-023707 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2025-09-04 | 2025-09-03 | PLX | Elze Christian | Dir | A - Grant | — | +7,500 | 7,500 | New | — |
| D | 2025-09-04 | 2025-09-03 | PLX | Elze Christian | Dir | A - Grant | $0.00 | +15.0K | 15.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-09-03 | A | A | 7,500 | — | 7,500 | I By Trust | — | — | (F1) Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the "Plan"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant. (F2) To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the Plan must be registered in the name of a trustee. |
| 2 | Derivative | Stock Options (Right to Buy) | 2025-09-03 | A | A | 15,000 | $0.00 | 15,000 | D | $1.64 · — to 2035-09-03 | 15,000 Common Stock | (F3) The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. |